10-KPeriod: FY2008

QUEST DIAGNOSTICS INC Annual Report, Year Ended Dec 31, 2008

Filed February 17, 2009For Securities:DGX

Summary

Quest Diagnostics Incorporated, a leader in diagnostic testing, reported $7.2 billion in net revenues for the fiscal year ended December 31, 2008. The company's strategy centers on enhancing the patient experience, driving quality through Six Sigma processes, leveraging its extensive network of laboratories and service centers, and investing in medical innovation and information technology. Quest Diagnostics aims to grow its business by acquiring new customers, expanding services to existing ones, and improving operational efficiency, with a long-term goal of outpacing the U.S. clinical laboratory industry's growth rate and increasing international revenue contribution. The company faces a competitive landscape with pressures from hospital-affiliated labs and other commercial providers. Key trends impacting the business include demographic shifts, increased reliance on diagnostic testing for personalized and preventative care, advancements in medical technology, and evolving healthcare information technologies. Regulatory scrutiny and evolving reimbursement policies from government and private payers remain significant factors influencing the company's financial performance and operational strategies.

Financial Statements
Beta
Revenue$7.25B
Cost of Revenue$4.26B
Gross Profit$2.99B
SG&A Expenses$1.74B
Operating Expenses$6.03B
Operating Income$1.22B
Interest Expense-$185.48M
Net Income$581.49M
EPS (Basic)$2.99
EPS (Diluted)$2.96
Shares Outstanding (Basic)194.28M
Shares Outstanding (Diluted)195.96M

Key Highlights

  • 1Quest Diagnostics generated $7.2 billion in net revenues for the fiscal year 2008, processing approximately 150 million test requisitions.
  • 2The company's strategy focuses on delivering a superior patient experience, driving quality through Six Sigma, leveraging extensive assets, leading in medical innovation, expanding geographic reach, and broadening its diagnostic scope.
  • 3Clinical testing accounted for over 90% of net revenues, with routine testing, anatomic pathology, and gene-based/esoteric testing being significant contributors.
  • 4The company is a leading provider in various specialized areas including cancer diagnostics, gene-based esoteric testing, and risk assessment services for the life insurance industry.
  • 5Quest Diagnostics is investing in healthcare information technology, with over 140,000 physicians having access to its Care360 products by the end of 2008.
  • 6The company highlighted the potential impact of economic slowdown on demand for services and faces ongoing competition, pricing pressures, and evolving regulatory and reimbursement environments.
  • 7A significant legal matter involving a former subsidiary, NID, resulted in a $316 million reserve related to alleged violations of civil and criminal statutes.

Frequently Asked Questions

In fiscal year 2008, Quest Diagnostics reported net revenues of $7.2 billion and processed approximately 150 million test requisitions. The company's revenue was primarily driven by its clinical testing business, which constituted over 90% of total net revenues.

Quest Diagnostics' primary revenue driver is its clinical testing business, which encompasses routine clinical testing, anatomic pathology, and gene-based/esoteric testing. Other segments include insurer services, clinical trials testing, diagnostic products, and healthcare information technology, which collectively contributed approximately 9% to 2008 net revenues.

Key risks include intense competition within the clinical testing market, pricing pressures from payers, potential adverse impacts from healthcare reform, evolving government and private payer reimbursement policies, challenges in integrating acquired businesses, and significant legal and regulatory risks, notably an ongoing matter involving a former subsidiary (NID) with a substantial reserve set aside.

Quest Diagnostics is focused on several growth strategies: enhancing the patient experience, improving operational efficiency through Six Sigma quality initiatives, leveraging its extensive network of assets and capabilities, investing in medical innovation and IT solutions (like Care360), and expanding its geographic reach internationally. The company also actively pursues strategic acquisitions.